KR101314369B1 - 치료학적 항체에 대한 조성물 및 사용 방법 - Google Patents

치료학적 항체에 대한 조성물 및 사용 방법 Download PDF

Info

Publication number
KR101314369B1
KR101314369B1 KR1020117001052A KR20117001052A KR101314369B1 KR 101314369 B1 KR101314369 B1 KR 101314369B1 KR 1020117001052 A KR1020117001052 A KR 1020117001052A KR 20117001052 A KR20117001052 A KR 20117001052A KR 101314369 B1 KR101314369 B1 KR 101314369B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
variable region
chain variable
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117001052A
Other languages
English (en)
Korean (ko)
Other versions
KR20110020914A (ko
Inventor
크리스토프 호이써
율리아 노이게바우어
에펠리네 샤트
슈테파니 울링거
막시밀리안 보이제츄레거
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101314369(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20110020914A publication Critical patent/KR20110020914A/ko
Application granted granted Critical
Publication of KR101314369B1 publication Critical patent/KR101314369B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020117001052A 2008-07-17 2009-07-15 치료학적 항체에 대한 조성물 및 사용 방법 Active KR101314369B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08160671.7 2008-07-17
EP08160671 2008-07-17
EP09160326.6 2009-05-15
EP09160326 2009-05-15
PCT/EP2009/059030 WO2010007082A1 (en) 2008-07-17 2009-07-15 Compositions and methods of use for therapeutic antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137019574A Division KR101545795B1 (ko) 2008-07-17 2009-07-15 치료학적 항체에 대한 조성물 및 사용 방법

Publications (2)

Publication Number Publication Date
KR20110020914A KR20110020914A (ko) 2011-03-03
KR101314369B1 true KR101314369B1 (ko) 2013-10-10

Family

ID=41073830

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117001052A Active KR101314369B1 (ko) 2008-07-17 2009-07-15 치료학적 항체에 대한 조성물 및 사용 방법
KR1020137019574A Active KR101545795B1 (ko) 2008-07-17 2009-07-15 치료학적 항체에 대한 조성물 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137019574A Active KR101545795B1 (ko) 2008-07-17 2009-07-15 치료학적 항체에 대한 조성물 및 사용 방법

Country Status (40)

Country Link
US (3) US8106163B2 (https=)
EP (1) EP2315780B8 (https=)
JP (2) JP5767109B2 (https=)
KR (2) KR101314369B1 (https=)
CN (1) CN102119174B (https=)
AR (1) AR072749A1 (https=)
AU (1) AU2009272771B2 (https=)
BR (1) BRPI0915928B8 (https=)
CA (1) CA2730063C (https=)
CL (1) CL2011000086A1 (https=)
CR (1) CR11863A (https=)
CU (1) CU23878B1 (https=)
CY (1) CY1116800T1 (https=)
DK (1) DK2315780T3 (https=)
DO (1) DOP2011000016A (https=)
EA (1) EA024492B1 (https=)
EC (1) ECSP11010761A (https=)
ES (1) ES2547270T3 (https=)
GE (1) GEP20146129B (https=)
HR (1) HRP20151227T1 (https=)
HU (1) HUE025778T2 (https=)
IL (1) IL210485A (https=)
JO (1) JO3149B1 (https=)
MA (1) MA32481B1 (https=)
MX (1) MX2011000616A (https=)
MY (1) MY158980A (https=)
NI (1) NI201100017A (https=)
NZ (1) NZ590057A (https=)
PE (1) PE20110563A1 (https=)
PL (1) PL2315780T3 (https=)
PT (1) PT2315780E (https=)
RS (1) RS54299B1 (https=)
SG (1) SG193805A1 (https=)
SI (1) SI2315780T1 (https=)
SM (1) SMP201100010B (https=)
SV (1) SV2011003807A (https=)
TW (1) TWI508742B (https=)
UY (1) UY31987A (https=)
WO (1) WO2010007082A1 (https=)
ZA (1) ZA201008952B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023184A2 (en) * 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
WO2012076670A2 (en) * 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
ES2989943T3 (es) * 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
AU2017204936B2 (en) 2016-02-10 2019-06-27 Novartis Ag Use of inhibitors of the activity or function of PI3K for the treatment of primary Sjogren's Syndrome
EP4628094A3 (en) * 2016-06-06 2025-12-31 City of Hope BAFF-R ANTIBODIES AND THEIR USES
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
KR102840867B1 (ko) * 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
BR112020024074A2 (pt) * 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
US20220220210A1 (en) * 2019-03-29 2022-07-14 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
KR20220093347A (ko) 2019-11-06 2022-07-05 노파르티스 아게 쇼그렌 증후군의 치료
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
WO2022031568A1 (en) 2020-08-04 2022-02-10 Novartis Ag Treatment of cll
AU2021320129B2 (en) 2020-08-04 2025-12-18 Novartis Ag Treatment of B cell malignancies
CN114149504B (zh) * 2020-09-07 2024-01-12 白先宏 Baff-r结合分子及其应用
IL302412A (en) * 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
TW202302147A (zh) 2021-05-04 2023-01-16 瑞士商諾華公司 使用抗baffr抗體治療狼瘡腎炎
IL308044A (en) 2021-05-04 2023-12-01 Novartis Ag Treatment of systemic lupus erythematosus using antibuffer antibodies
AR127163A1 (es) * 2021-09-29 2023-12-27 Dragonfly Therapeutics Inc Anticuerpos dirigidos a baff-r y uso de estos
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
WO2025058962A1 (en) * 2023-09-11 2025-03-20 Absci Corporation High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
WO2025131888A1 (en) 2023-12-19 2025-06-26 Basf Se Modified alkoxylated polyalkylene imines or modified alkoxylated polyamines
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070107687A (ko) * 2004-12-31 2007-11-07 제넨테크, 인크. Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100447244C (zh) * 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070107687A (ko) * 2004-12-31 2007-11-07 제넨테크, 인크. Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides

Also Published As

Publication number Publication date
KR20110020914A (ko) 2011-03-03
CA2730063C (en) 2017-04-18
US20120195913A1 (en) 2012-08-02
MX2011000616A (es) 2011-02-24
AU2009272771B2 (en) 2012-09-20
JO3149B1 (ar) 2017-09-20
IL210485A0 (en) 2011-03-31
HK1150839A1 (en) 2012-01-13
DK2315780T3 (en) 2015-10-19
EP2315780A1 (en) 2011-05-04
CN102119174B (zh) 2015-01-21
MA32481B1 (fr) 2011-07-03
SV2011003807A (es) 2011-03-23
EA201100191A1 (ru) 2011-08-30
BRPI0915928A2 (pt) 2015-11-03
NZ590057A (en) 2012-08-31
JP6077587B2 (ja) 2017-02-08
CN102119174A (zh) 2011-07-06
EP2315780B1 (en) 2015-08-19
PT2315780E (pt) 2015-11-30
DOP2011000016A (es) 2011-02-15
EP2315780B8 (en) 2015-09-23
JP2011527896A (ja) 2011-11-10
PE20110563A1 (es) 2011-08-29
RS54299B1 (sr) 2016-02-29
HRP20151227T1 (hr) 2015-12-18
TW201006493A (en) 2010-02-16
AR072749A1 (es) 2010-09-15
ECSP11010761A (es) 2011-02-28
KR101545795B1 (ko) 2015-08-19
BRPI0915928B8 (pt) 2021-05-25
UY31987A (es) 2010-02-26
IL210485A (en) 2015-03-31
ES2547270T3 (es) 2015-10-05
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
AU2009272771A1 (en) 2010-01-21
BRPI0915928B1 (pt) 2020-10-20
EA024492B1 (ru) 2016-09-30
CU20110013A7 (es) 2012-06-21
JP5767109B2 (ja) 2015-08-19
US9340620B2 (en) 2016-05-17
CA2730063A1 (en) 2010-01-21
HUE025778T2 (en) 2016-05-30
GEP20146129B (en) 2014-08-11
KR20130098432A (ko) 2013-09-04
CL2011000086A1 (es) 2011-07-01
CY1116800T1 (el) 2017-03-15
JP2015133983A (ja) 2015-07-27
CR11863A (es) 2011-02-11
TWI508742B (zh) 2015-11-21
SG193805A1 (en) 2013-10-30
NI201100017A (es) 2012-08-17
MY158980A (en) 2016-11-30
ZA201008952B (en) 2012-01-25
US8106163B2 (en) 2012-01-31
SMP201100010B (it) 2011-09-09
SI2315780T1 (sl) 2015-11-30
CU23878B1 (es) 2013-04-19
US9382326B2 (en) 2016-07-05
WO2010007082A1 (en) 2010-01-21
PL2315780T3 (pl) 2016-01-29
US20100021452A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
KR101314369B1 (ko) 치료학적 항체에 대한 조성물 및 사용 방법
US8715657B2 (en) Therapeutic antibodies binding IL12Rβ1
US20250034270A1 (en) Compositions and methods of use for therapeutic antibodies
HK1150839B (en) Compositions and methods of use for therapeutic antibodies

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160831

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170831

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20180903

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190829

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20200917

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20210827

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20220830

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 13